-
Something wrong with this record ?
The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma
A. Vdovin, T. Jelinek, D. Zihala, T. Sevcikova, M. Durech, H. Sahinbegovic, R. Snaurova, D. Radhakrishnan, M. Turi, Z. Chyra, T. Popkova, O. Venglar, M. Hrdinka, R. Hajek, M. Simicek
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2015
Free Medical Journals
from 2010
Nature Open Access
from 2010-12-01
PubMed Central
from 2012
Europe PubMed Central
from 2012
ProQuest Central
from 2010-01-01
Open Access Digital Library
from 2015-01-01
Open Access Digital Library
from 2015-01-01
Medline Complete (EBSCOhost)
from 2012-11-01
Health & Medicine (ProQuest)
from 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2010
Springer Nature OA/Free Journals
from 2010-12-01
- MeSH
- Apoptosis MeSH
- Bortezomib pharmacology therapeutic use MeSH
- Deubiquitinating Enzymes MeSH
- Immunoglobulins MeSH
- Proteasome Inhibitors * pharmacology MeSH
- Humans MeSH
- Multiple Myeloma * drug therapy genetics metabolism MeSH
- Proteasome Endopeptidase Complex metabolism MeSH
- Proteomics MeSH
- Ubiquitin-Specific Proteases MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Serum monoclonal immunoglobulin (Ig) is the main diagnostic factor for patients with multiple myeloma (MM), however its prognostic potential remains unclear. On a large MM patient cohort (n = 4146), we observe no correlation between serum Ig levels and patient survival, while amount of intracellular Ig has a strong predictive effect. Focused CRISPR screen, transcriptional and proteomic analysis identify deubiquitinase OTUD1 as a critical mediator of Ig synthesis, proteasome inhibitor sensitivity and tumor burden in MM. Mechanistically, OTUD1 deubiquitinates peroxiredoxin 4 (PRDX4), protecting it from endoplasmic reticulum (ER)-associated degradation. In turn, PRDX4 facilitates Ig production which coincides with the accumulation of unfolded proteins and higher ER stress. The elevated load on proteasome ultimately potentiates myeloma response to proteasome inhibitors providing a window for a rational therapy. Collectively, our findings support the significance of the Ig production machinery as a biomarker and target in the combinatory treatment of MM patients.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032696
- 003
- CZ-PrNML
- 005
- 20230131151702.0
- 007
- ta
- 008
- 230120s2022 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41467-022-34654-2 $2 doi
- 035 __
- $a (PubMed)36357400
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Vdovin, Alexander $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Syllabova 19, 703 00, Czech Republic $u Department of Hematooncology, University Hospital Ostrava, Ostrava, 17. listopadu 1790/5, 708 00, Czech Republic $u Faculty of Science, University of Ostrava, Ostrava, 30. dubna 22, 701 03, Czech Republic $1 https://orcid.org/0000000308104659
- 245 14
- $a The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma / $c A. Vdovin, T. Jelinek, D. Zihala, T. Sevcikova, M. Durech, H. Sahinbegovic, R. Snaurova, D. Radhakrishnan, M. Turi, Z. Chyra, T. Popkova, O. Venglar, M. Hrdinka, R. Hajek, M. Simicek
- 520 9_
- $a Serum monoclonal immunoglobulin (Ig) is the main diagnostic factor for patients with multiple myeloma (MM), however its prognostic potential remains unclear. On a large MM patient cohort (n = 4146), we observe no correlation between serum Ig levels and patient survival, while amount of intracellular Ig has a strong predictive effect. Focused CRISPR screen, transcriptional and proteomic analysis identify deubiquitinase OTUD1 as a critical mediator of Ig synthesis, proteasome inhibitor sensitivity and tumor burden in MM. Mechanistically, OTUD1 deubiquitinates peroxiredoxin 4 (PRDX4), protecting it from endoplasmic reticulum (ER)-associated degradation. In turn, PRDX4 facilitates Ig production which coincides with the accumulation of unfolded proteins and higher ER stress. The elevated load on proteasome ultimately potentiates myeloma response to proteasome inhibitors providing a window for a rational therapy. Collectively, our findings support the significance of the Ig production machinery as a biomarker and target in the combinatory treatment of MM patients.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a inhibitory proteasomu $x farmakologie $7 D061988
- 650 12
- $a mnohočetný myelom $x farmakoterapie $x genetika $x metabolismus $7 D009101
- 650 _2
- $a bortezomib $x farmakologie $x terapeutické užití $7 D000069286
- 650 _2
- $a proteomika $7 D040901
- 650 _2
- $a apoptóza $7 D017209
- 650 _2
- $a proteasomový endopeptidasový komplex $x metabolismus $7 D046988
- 650 _2
- $a imunoglobuliny $7 D007136
- 650 _2
- $a deubikvitinasy $7 D000072017
- 650 _2
- $a specifické proteázy ubikvitinu $7 D064570
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Jelinek, Tomas $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Syllabova 19, 703 00, Czech Republic $u Department of Hematooncology, University Hospital Ostrava, Ostrava, 17. listopadu 1790/5, 708 00, Czech Republic
- 700 1_
- $a Zihala, David $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Syllabova 19, 703 00, Czech Republic $u Department of Hematooncology, University Hospital Ostrava, Ostrava, 17. listopadu 1790/5, 708 00, Czech Republic $u Faculty of Science, University of Ostrava, Ostrava, 30. dubna 22, 701 03, Czech Republic
- 700 1_
- $a Sevcikova, Tereza $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Syllabova 19, 703 00, Czech Republic $u Department of Hematooncology, University Hospital Ostrava, Ostrava, 17. listopadu 1790/5, 708 00, Czech Republic $u Faculty of Science, University of Ostrava, Ostrava, 30. dubna 22, 701 03, Czech Republic
- 700 1_
- $a Durech, Michal $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Syllabova 19, 703 00, Czech Republic $u Department of Hematooncology, University Hospital Ostrava, Ostrava, 17. listopadu 1790/5, 708 00, Czech Republic $1 https://orcid.org/0000000240544315
- 700 1_
- $a Sahinbegovic, Hana $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Syllabova 19, 703 00, Czech Republic $u Department of Hematooncology, University Hospital Ostrava, Ostrava, 17. listopadu 1790/5, 708 00, Czech Republic $u Faculty of Science, University of Ostrava, Ostrava, 30. dubna 22, 701 03, Czech Republic
- 700 1_
- $a Snaurova, Renata $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Syllabova 19, 703 00, Czech Republic $u Department of Hematooncology, University Hospital Ostrava, Ostrava, 17. listopadu 1790/5, 708 00, Czech Republic $u Faculty of Science, University of Ostrava, Ostrava, 30. dubna 22, 701 03, Czech Republic $1 https://orcid.org/000000026979844X
- 700 1_
- $a Radhakrishnan, Dhwani $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Syllabova 19, 703 00, Czech Republic $u Department of Hematooncology, University Hospital Ostrava, Ostrava, 17. listopadu 1790/5, 708 00, Czech Republic $u Faculty of Science, University of Ostrava, Ostrava, 30. dubna 22, 701 03, Czech Republic
- 700 1_
- $a Turi, Marcello $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Syllabova 19, 703 00, Czech Republic $u Department of Hematooncology, University Hospital Ostrava, Ostrava, 17. listopadu 1790/5, 708 00, Czech Republic $u Faculty of Science, University of Ostrava, Ostrava, 30. dubna 22, 701 03, Czech Republic $1 https://orcid.org/0000000287601794
- 700 1_
- $a Chyra, Zuzana $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Syllabova 19, 703 00, Czech Republic $u Department of Hematooncology, University Hospital Ostrava, Ostrava, 17. listopadu 1790/5, 708 00, Czech Republic
- 700 1_
- $a Popkova, Tereza $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Syllabova 19, 703 00, Czech Republic $u Department of Hematooncology, University Hospital Ostrava, Ostrava, 17. listopadu 1790/5, 708 00, Czech Republic
- 700 1_
- $a Venglar, Ondrej $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Syllabova 19, 703 00, Czech Republic $u Department of Hematooncology, University Hospital Ostrava, Ostrava, 17. listopadu 1790/5, 708 00, Czech Republic $u Faculty of Science, University of Ostrava, Ostrava, 30. dubna 22, 701 03, Czech Republic
- 700 1_
- $a Hrdinka, Matous $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Syllabova 19, 703 00, Czech Republic $u Department of Hematooncology, University Hospital Ostrava, Ostrava, 17. listopadu 1790/5, 708 00, Czech Republic $1 https://orcid.org/0000000229812825
- 700 1_
- $a Hajek, Roman $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Syllabova 19, 703 00, Czech Republic $u Department of Hematooncology, University Hospital Ostrava, Ostrava, 17. listopadu 1790/5, 708 00, Czech Republic
- 700 1_
- $a Simicek, Michal $u Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Syllabova 19, 703 00, Czech Republic. michal.simicek@fno.cz $u Department of Hematooncology, University Hospital Ostrava, Ostrava, 17. listopadu 1790/5, 708 00, Czech Republic. michal.simicek@fno.cz $u Faculty of Science, University of Ostrava, Ostrava, 30. dubna 22, 701 03, Czech Republic. michal.simicek@fno.cz $1 https://orcid.org/0000000323882723
- 773 0_
- $w MED00184850 $t Nature communications $x 2041-1723 $g Roč. 13, č. 1 (2022), s. 6820
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36357400 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131151658 $b ABA008
- 999 __
- $a ok $b bmc $g 1891440 $s 1184031
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 13 $c 1 $d 6820 $e 20221110 $i 2041-1723 $m Nature communications $n Nat Commun $x MED00184850
- LZP __
- $a Pubmed-20230120
